Cargando…
Anti-RANKL Inhibits Thymic Function and Causes DRONJ in Mice
BACKGROUND: Denosumab, a human monoclonal antibody against receptor activator of nuclear factor-kappa B ligand (RANKL), is a novel bone antiresorptive agent used in patients with osteoporosis or metastatic bone cancer. Denosumab-related osteonecrosis of the jaw (DRONJ) has been recently reported in...
Autores principales: | Nakamura, Yusuke, Kikuiri, Takashi, Sugiyama, Takahiro, Maeda, Ayako, Izumiyama, Daisuke, Yahata, Daigo, Yoshimura, Yoshitaka, Shirakawa, Tetsuo, Kitagawa, Yoshimasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033356/ https://www.ncbi.nlm.nih.gov/pubmed/35464103 http://dx.doi.org/10.1155/2022/9299602 |
Ejemplares similares
-
Bone resorption improvement by conditioned medium of stem cells from human exfoliated deciduous teeth in ovariectomized mice
por: Maeda, Ayako, et al.
Publicado: (2022) -
A rare case of multiple brain abscesses caused by apical periodontitis of deciduous teeth in congenital heart disease: a case report
por: Takahashi, Shizuka, et al.
Publicado: (2022) -
Administration of RANKL boosts thymic regeneration upon bone marrow transplantation
por: Lopes, Noella, et al.
Publicado: (2017) -
Identification of Novel Thymic Epithelial Cell Subsets Whose Differentiation Is Regulated by RANKL and Traf6
por: Danzl, Nichole M., et al.
Publicado: (2014) -
Correction: Identification of Novel Thymic Epithelial Cell Subsets Whose Differentiation Is Regulated by RANKL and Traf6
Publicado: (2014)